Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects

Recombinant glucagon-like peptide-1 (7–36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5d by prandial subcutaneous injections (PSI) (76nmol 30min before meals, four times daily; a total of 302·4nmol/24h) or by continuous subcutaneous infusion (CSI) (12·7nmol/h; a total of 304·8nmol/24h). This was performed in nineteen healthy obese subjects (mean age 44·2 (sem 2·5) years; BMI 39·0 (sem 1·2)kg/m2) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15% reduction in mean food intake per meal (P=0·02) after 5d treatment. A weight loss of 0·55 (sem 0·2) kg (P<0·05) was registered after 5d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI (P<0·001) and CSI (P<0·05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.

[1]  J. Holst,et al.  Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships , 1995, Diabetologia.

[2]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[3]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[4]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  J. Holst,et al.  Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes , 2001, Journal of internal medicine.

[6]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[7]  P. Hellström,et al.  Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial , 2000, European Journal of Nuclear Medicine.

[8]  E. Näslund.  Gastric Emptying: Comparison of Scintigraphic, Polyethylene Glycol Dilution, and Paracetamol Tracer Assessment Techniques , 2000, Scandinavian journal of gastroenterology.

[9]  J. Holst,et al.  GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. , 1999, The American journal of physiology.

[10]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[11]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[12]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[13]  D Conen,et al.  Glucagon-like peptide-1: a potent regulator of food intake in humans , 1999, Gut.

[14]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[15]  P. J. Larsen,et al.  Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. , 1998, Diabetes.

[16]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[17]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[18]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[19]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[20]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[21]  J. Holst,et al.  Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I , 1996, Diabetes.

[22]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[23]  J. Holst,et al.  Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM , 1994, Diabetes Care.

[24]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[25]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[26]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[27]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[28]  S. Rössner,et al.  Effects of a high-protein meal (meat) and a high-carbohydrate meal (vegetarian) on satiety measured by automated computerized monitoring of subsequent food intake, motivation to eat and food preferences. , 1990, International journal of obesity.

[29]  S. Bloom,et al.  Characterization of glucagon-like peptide-1-(7–36)amide in the hypothalamus , 1989, Brain Research.

[30]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[31]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[32]  R. Shapiro,et al.  The central neural connections of the area postrema of the rat , 1985, The Journal of comparative neurology.